Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of SC10914 in germline BRCA-mutated advanced ovarian cancer after failure of at least 2 prior chemotherapy lines
CTR20200059Phase 2Active
- Sponsor
- Qingfeng Pharmaceutical Group
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SC10914 in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Qingfeng Pharmaceutical Group. Started Dec 2020; status: active.
02
Drugs
SC10914
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on CTR20200059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200059.